Any current/future new fundraising through debt or equity?

No need for fundraising: The company currently has around ₹400 crores liquidity in hand and is well-capitalized. No plans to raise capital: For the next five years, there is no intention to raise funds through debt or equity. Sufficient cash flow: The existing business, especially the supply chain segment, is expected to be cash positive soon and generates adequate cash to fund other nascent businesses like Retailer Shakti and Geno Health app. Focus on efficient use of current liquidity: While some investments may be planned (e.g., in diagnostics), there are no firm plans for additional fundra

Any current/future capex/capital investment/strategic investment?

No firm plans currently to use liquidity for operational burn. Potential acquisition in the diagnostic space once existing diagnostic investments show traction; clarity expected by year-end. ₹30 crores CAPEX planned for future business growth, including warehouses. Expansion from 7 warehouses is cautious; focus on improving efficiency and profitability before adding more. Some capital will be invested in the B2B Retailer Shakti and the upcoming AI-based Genu Health app focused on wellness, diagnostics, and emergency care. Balance capital deployment plans are still being finalized post-merger a

Future growth expectations in sales/revenue/volumes?

Both Sastasundar Health Buddy Business and Retailer Shakti are expected to rapidly grow over the next 2-3 years (Page 15). Growth will be rapid but not in a "hyper growth" stage due to the nature of the pharmaceutical supply chain and time needed to digitize customers (Page 16). Growth rate over the next 5 years may be similar to the past 5 years, implying steady and rapid expansion (Page 16). Next 1-2 quarters may see consolidation with slower growth, especially in Health Buddy supply chain, but after that, rapid growth is expected (Pages 10, 16). Volume growth is supported by guaranteed next

Future growth expectations in earnings/operating earnings/profits/EPS?

Banwari Lal Mittal expects rapid growth in both Sastasundar Health Buddy and Retailer Shakti businesses over the next 2-3 years. Growth will be rapid but not hyper-growth due to the time needed to build pharmaceutical supply chains and digital customer adoption in India. The company’s growth rate over the next 5 years is anticipated to be similar to the past 5 years, maintaining rapid expansion. Health Buddy supply chain is already EBITDA positive and expected to maintain profitability. Retailer Shakti and Genu Path Labs may incur losses short-term due to ongoing investments but will grow. The

Health X Platform LtdQ1 FY24Healthcare Services

Health X Platform Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹289.5Market Cap: ₹921 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Both Sastasundar Health Buddy Business and Retailer Shakti are expected to rapidly grow over the next 2-3 years (Page 15).
Growth will be rapid but not in a "hyper growth" stage due to the nature of the pharmaceutical supply chain and time needed to digitize customers (Page 16).
Growth rate over the next 5 years may be similar to the past 5 years, implying steady and rapid expansion (Page 16).
Next 1-2 quarters may see consolidation with slower growth, especially in Health Buddy supply chain, but after that, rapid growth is expected (Pages 10, 16).
Volume growth is supported by guaranteed next-day delivery and availability through Retailer Shakti improving inventory management for B2B customers (Page 18).
The business aims to be one of the top 10 consolidated players in India’s large pharmaceutical distribution market (Page 17).

Margin guidance

Category 3

Banwari Lal Mittal expects rapid growth in both Sastasundar Health Buddy and Retailer Shakti businesses over the next 2-3 years.
Growth will be rapid but not hyper-growth due to the time needed to build pharmaceutical supply chains and digital customer adoption in India.
The company’s growth rate over the next 5 years is anticipated to be similar to the past 5 years, maintaining rapid expansion.
Health Buddy supply chain is already EBITDA positive and expected to maintain profitability.
Retailer Shakti and Genu Path Labs may incur losses short-term due to ongoing investments but will grow.
The next 1-2 quarters may see consolidation with slower growth, but growth is projected to accelerate afterward.
There is confidence in sustainable gross margin around 10%, supporting scalable revenue and profit growth.

See what Health X Platform Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No need for fundraising: The company currently has around ₹400 crores liquidity in hand and is well-capitalized.
No plans to raise capital: For the next five years, there is no intention to raise funds through debt or equity.
Sufficient cash flow: The existing business, especially the supply chain segment, is expected to be cash positive soon and generates adequate cash to fund other nascent businesses like Retailer Shakti and Geno Health app.
Focus on efficient use of current liquidity: While some investments may be planned (e.g., in diagnostics), there are no firm plans for additional fundraising at present.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Sastasundar Ventures Limited. However, key points related to order fulfillment and supply chain include: - Availability and guaranteed next-day delivery to B2B customers (pharmacy stores) is emphasized as crucial for managing inventory efficiently (Page 18). - Retailer Shakti ensures every B2B customer gets next-day guaranteed delivery, improving inventory turnover from 50 days to about 10 days (Page 18). - The company has 7 warehouses, with plans to add approximately 17 more to support growing operations and distribution capacity (Page 11). - Volume and demand management are linked closely to efficient logistics and reduced discounts in the e-pharmacy segment (Pages 8–10). No direct data is provided on order backlog or pending orders.

See what Health X Platform Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

No firm plans currently to use liquidity for operational burn.
Potential acquisition in the diagnostic space once existing diagnostic investments show traction; clarity expected by year-end.
₹30 crores CAPEX planned for future business growth, including warehouses.
Expansion from 7 warehouses is cautious; focus on improving efficiency and profitability before adding more.
Some capital will be invested in the B2B Retailer Shakti and the upcoming AI-based Genu Health app focused on wellness, diagnostics, and emergency care.
Balance capital deployment plans are still being finalized post-merger and simplification.
Currently holding around ₹350–400 crores in liquid investments, no immediate need for additional fundraising.

Track Health X Platform Ltd — get its next earnings analysis in your feed

How does Health X Platform Ltd rank vs peers in Healthcare Services?

Pro feature

ThisHealth X Platform Ltd

Rev 2Mar 3

See where Health X Platform Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Health X Platform Ltd rank in Healthcare Services?

Compare Health X Platform Ltd against every Healthcare Services company (Q1 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Health X Platform Ltd's management said in earlier quarters

Others in Healthcare Services this season

Rainbow Childrens Medicare Ltd (Q2 FY27)
Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how
Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio

Compare:vs Apollo Hospitals Enterprise Ltd vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →